Blennow, Kaj

Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia

Tarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 349

Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease

Portelius, E., Bogdanovic, N., Gustavsson, M. K., Volkmann, I., Brinkmalm, G., Zetterberg, H., Winblad, B., & Blennow, K. (2010) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 348

Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau

Hohman, T. J., Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., Mukherjee, S., et al. (2018) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 340

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 328

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 324

Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 321

Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury

Öst, M., Nylén, K., Csajbok, L., Öhrfelt, A. O., Tullberg, M., Wikkelsö, C., Nellgård, P., Rosengren, L., Blennow, K., & Nellgård, B. (2006) · Neurology

Traumatic Brain Injury and Neurovascular DisturbancesTraumatic Brain Injury Research

Cited by 321

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease

Bellaver, B., Povala, G., Ferreira, P. C. L., Ferrari-Souza, J. P., Leffa, D. T., Lussier, F. Z., Benedet, A. L., Ashton, N. J., Triana-Baltzer, G., Kolb, H. C., et al. (2023) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 319

Two phase 3 trials of gantenerumab in early Alzheimer's disease

Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., Wojtowicz, J., Blennow, K., Bittner, T., Black, S. E., et al. (2023) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 314

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

Mattsson-Carlgren, N., Salvadó, G., Ashton, N. J., Tideman, P., Stomrud, E., Zetterberg, H., Ossenkoppele, R., Betthauser, T. J., Cody, K. A., Jonaitis, E. M., et al. (2023) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 309

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging

Therriault, J., Pascoal, T. A., Lussier, F. Z., Tissot, C., Chamoun, M., Bezgin, G., Servaes, S., Benedet, A. L., Ashton, N. J., Karikari, T. K., et al. (2022) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 308

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 303

Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma

Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 301

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

Blennow, K. (2017) · Neurology and Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 295

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 293

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 290

Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment

Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 287

Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape

Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 283

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 266

CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival

Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 263

Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease

Dean, D. C., Hurley, S. A., Kecskemeti, S. R., O’Grady, J. P., Canda, C., Davenport-Sis, N. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Asthana, S., et al. (2017) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 252

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

Brum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2023) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 248

Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration

Weston, P. S. J., Poole, T., Ryan, N. S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I. B., Ahsan, R. L., Pemberton, H., et al. (2017) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 245

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

Mielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 244